Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Folfiri

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    146 result(s) found for: Folfiri. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2016-001627-31 Sponsor Protocol Number: CanStem303C Start Date*: 2016-12-20
    Sponsor Name:Sumitomo Dainippon Pharma Oncology, Inc.
    Full Title: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)
    Medical condition: Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic (Stage IV).
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) BE (Completed) CZ (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022983-11 Sponsor Protocol Number: BP25438 Start Date*: 2011-01-24
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A randomized, multicenter, open-label phase II study of RO5083945 in combination with FOLFIRI versus FOLFIRI plus cetuximab or FOLFIRI alone as second line treatment in patients with KRAS wild-type...
    Medical condition: Metastatic colorectal cancer, KRAS wild-type (WT) or mutant, with disease progression after first line treatment with an oxaliplatin-containing regimen
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Completed) BE (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001422-16 Sponsor Protocol Number: CT/14.01 Start Date*: 2015-10-13
    Sponsor Name:Hellenic Oncology Research Group
    Full Title: An open label, non-randomized, phase two trial in metastatic colorectal cancer (mCRC) with the combination of mFOLFIRI plus Aflibercept as first treatment: MINOAS trial
    Medical condition: Metastatic colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003779-20 Sponsor Protocol Number: SCO101-001 Start Date*: 2020-01-28
    Sponsor Name:Scandion Oncology A/S
    Full Title: An open-label phase II prospective clinical trial to investigate safety, tolerability, maximum tolerated dose and anti-tumor effect for SCO-101 in combination with FOLFIRI as a safe and efficient t...
    Medical condition: Metastatic or advanced colorectal cancer (mCRC) with acquired resistance to chemotherapy 
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing) DE (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003669-87 Sponsor Protocol Number: M14-064 Start Date*: 2018-03-19
    Sponsor Name:Abbvie Deutschland GmbH & Co. KG
    Full Title: Phase 2 Study Comparing Efficacy and Safety of ABT-165 and FOLFIRI vs Bevacizumab and FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine/Oxaliplatin and Bevacizumab
    Medical condition: metastatic adenocarcinoma of the colon or rectum previously treated with a regimen containing fluoropyrimidine/oxaliplatin and bevacizumab
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-012151-23 Sponsor Protocol Number: SPON 671-09 Start Date*: 2009-11-11
    Sponsor Name:Cardiff University
    Full Title: A randomised phase II study of Irinotecan, 5-Fluorouracil and Folinic Acid (FOLFIRI) with or without the addition of an endothelin receptor antagonist in patients with metastatic colorectal cancer ...
    Medical condition: Metastatic Colorectal Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000325-21 Sponsor Protocol Number: A6181122 Start Date*: 2007-05-02
    Sponsor Name:Pfizer Inc. - 235 East 42nd Street - New York - 10017
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB IN METASTATIC COLORECTAL CANCER PATIENTS RECEIVING IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFIRI) AS FIRST LINE TREATMENT
    Medical condition: first-line treatment of patients with metastatic colorectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IE (Completed) DE (Completed) AT (Completed) ES (Completed) HU (Completed) BE (Completed) PT (Completed) CZ (Completed) GB (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2016-002738-55 Sponsor Protocol Number: 69HCL16-0134 Start Date*: 2017-01-06
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis ( IPOXA )
    Medical condition: Patients with peritoneal carcinosis of colorectal origin and uncertain resectability with an indication for systemic chemotherapy compatible with the FOLFIRI + bevacizumab combination.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10052171 Peritoneal carcinoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019564-37 Sponsor Protocol Number: GMIHO-010/2009 Start Date*: 2011-05-02
    Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation – Hämatologie und Onkologie mbH
    Full Title: A Double-blind Placebo-controlled Randomized Multicenter Phase II Trial of Skin Toxicity Treatment in Subjects with Metastatic Colorectal Carcinoma Receiving Panitumumab
    Medical condition: Skin toxicity treatment in patients with wild-type KRAS metastatic colorectal cancer (mCRC) treated with panitumumab • In first-line in combination with FOLFOX • In second-line in combination wit...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003047-19 Sponsor Protocol Number: Sym004-09 Start Date*: 2016-03-02
    Sponsor Name:Symphogen A/S
    Full Title: An Open label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination with FOLFIRI in Patients with Metastatic Colorectal Cancer Progressing after First-Line Therapy
    Medical condition: Patients with locally advanced or metastatic CRC, wild type KRAS/NRAS (exon 2, 3, 4) will be enrolled.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-003754-61 Sponsor Protocol Number: GS-US-295-0203 Start Date*: 2012-03-08
    Sponsor Name:GILEAD SCIENCE INC.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Aden...
    Medical condition: Metastatic KRAS Mutant Colorectal Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014041-81 Sponsor Protocol Number: 2906 Start Date*: 2009-11-13
    Sponsor Name:GOIM GRUPPO ONCOLOGICO MERIDIONALE
    Full Title: Optimal strategy in K-ras wild type metastatic colorectal cancer patients: cetuximab plus FOLFIRI followed by FOLFOX+/- cetuximab (GOIM multicenter program)
    Medical condition: k-ras wild type metastatic colorectal cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000221-42 Sponsor Protocol Number: IIBSP-IRI-2011-134 Start Date*: 2012-05-03
    Sponsor Name:Fundación Institut de Recerca Hospital Sant Pau
    Full Title: Estudio farmacogenético fase II randomizado para evaluar la eficacia y seguridad del esquema FOLFIRI con altas dosis de irinotecán (FOLFIRI-AD) en pacientes con cáncer colorrectal metastásico de a...
    Medical condition: metastatic colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-008282-36 Sponsor Protocol Number: GPICD–CR–0801 Start Date*: 2010-05-07
    Sponsor Name:Grupo de Investigação do Cancro Digestivo
    Full Title: Randomized, open-label phase II study evaluating the safety and efficacy of Cetuximab plus modified FOLFOX - 6 versus modified FOLFOX - 6 alone as 2nd line therapy after progression on the 1st line...
    Medical condition: Colorectal cancer KRAS wild-type
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005547-27 Sponsor Protocol Number: GO28074 Start Date*: 2012-10-24
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE II, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF FOLFIRI + MEHD7945A VERSUS FOLFIRI + CETUXIMAB IN SECOND LINE IN PATIENTS WITH KRAS WILD-TYPE METASTATIC ...
    Medical condition: Colorectal cancer that does not carry mutation in the KRAS gene
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001167 Adenocarcinoma of colon PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010029 Colorectal cancer NOS LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038019 Rectal adenocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) BE (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003244-23 Sponsor Protocol Number: SICOG13/02 Start Date*: 2014-03-19
    Sponsor Name:S.I.C.O.G. ONLUS
    Full Title: B-FOLFIRI followed by B-FOLFOX/B-XELOX or the reverse sequence versus standard B-FOLFIRI for the first-line treatment of metastatic colorectal cancer: a randomized SICOG study. SEveSTA study (Seq...
    Medical condition: Unresectable and metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002866-65 Sponsor Protocol Number: M14-217 Start Date*: 2014-12-05
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: Randomized, Blinded, Multicenter, Phase 2 Study Comparing Veliparib Plus FOLFIRI ± Bevacizumab Versus Placebo Plus FOLFIRI ± Bevacizumab in Previously Untreated Metastatic Colorectal Cancer
    Medical condition: Untreated Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) DE (Completed) BE (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005301-19 Sponsor Protocol Number: 20060579 Start Date*: 2009-06-09
    Sponsor Name:Amgen Inc
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KR...
    Medical condition: Second-line treatment of KRAS mutant-type metastatic colorectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006283-30 Sponsor Protocol Number: A4061034 Start Date*: 2008-02-13
    Sponsor Name:Pfizer, S.A.
    Full Title: Estudio aleatorizado en fase 2 de Folfox o Folfiri con AG-013736 o Bevacizumab en pacientes con cáncer colorrectal metastásico después del fracaso a una pauta de primera línea con irinotecan u oxal...
    Medical condition: Segunda linea de tratamiento en pacientes con carcinoma colorectal. Second line treatment of patients with metastatic carcinoma of colon and rectum
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052362 Metastatic colorectal cancer LLT
    9.1 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) FR (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021037-32 Sponsor Protocol Number: I4T-MC-JVBB(e) Start Date*: 2011-01-12
    Sponsor Name:Eli Lilly and Company Limited, Indianapolis
    Full Title: A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progress...
    Medical condition: Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10010036 Colorectal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) FR (Completed) AT (Completed) NL (Completed) ES (Completed) PT (Completed) DE (Completed) IT (Completed) SE (Completed) BE (Completed) DK (Completed) GR (Completed) HU (Completed) SI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:44:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA